Attention investors who purchased shares of Pfenex Inc. before August 10, 2020:
Rigrodsky & Long is investigating potential claims against the board of directors of Pfenex Inc. concerning possible breaches of fiduciary duty and other violations of law related to the Company’s agreement to be acquired by Ligand Pharmaceuticals Incorporated.
Rigrodsky & Long, P.A. announces that it is investigating Pfenex Inc. (“Pfenex”) (NYSE American: PFNX) regarding possible breaches of fiduciary duties and other violations of law related to Pfenex’s agreement to be acquired by Ligand Pharmaceuticals Incorporated (NASADAQ GM: LGND). Under the terms of the agreement, shareholders of Pfenex will receive $12.00 in cash and one contingent value right (“CVR”) for each share of Pfenex they own.
If you would like to discuss this investigation and your rights cost and obligation free, please contact Seth D. Rigrodsky or Gina M. Serra toll free at (888) 969-4242 or by e-mail at email@example.com.
Rigrodsky & Long, P.A., with offices in Delaware and New York, has recovered hundreds of millions of dollars on behalf of investors and achieved substantial corporate governance reforms in securities fraud and corporate class actions nationwide.
Attorney advertising. Prior results do not guarantee a similar outcome.